Time trends and characteristics of men choosing watchful waiting for initial treatment of localized prostate cancer: results from CaPSURE.
about
Comprehensive validation of published immunohistochemical prognostic biomarkers of prostate cancer -what has gone wrong? A blueprint for the way forward in biomarker studiesEffect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT)ProCOC: the prostate cancer outcomes cohort study.Treatment decisions for localized prostate cancer: a concept mapping approachRadical prostatectomy: value of prostate MRI in surgical planning.Patient perspective on watchful waiting/active surveillance for localized prostate cancer.American trends in expectant management utilization for prostate cancer from 2000 to 2009.Outcomes of active surveillance for men with intermediate-risk prostate cancer.Self-rated health as a tool for estimating health-adjusted life expectancy among patients newly diagnosed with localized prostate cancer: a preliminary study.Management of complications of androgen deprivation therapy in the older man.Men's perspectives on selecting their prostate cancer treatmentIncreasing use of observation among men at low risk for prostate cancer mortality.PROMIS--Prostate MR imaging study: A paired validating cohort study evaluating the role of multi-parametric MRI in men with clinical suspicion of prostate cancer.Delayed versus immediate surgical intervention and prostate cancer outcomePIVOT and the challenges of localized prostate cancer care.Quality of life in men undergoing active surveillance for localized prostate cancer.Continuing controversy over monitoring men with localized prostate cancer: a systematic review of programs in the prostate specific antigen era.Impact of race on survival in patients with clinically nonmetastatic prostate cancer who deferred primary treatment.Psychosocial barriers to active surveillance for the management of early prostate cancer and a strategy for increased acceptance.Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era.Watchful waiting and active surveillance: the current position.Critical review: is watchful waiting a viable management option for older men with prostate cancer?Screening, risk assessment, and the approach to therapy in patients with prostate cancer.Diagnostic and prognostic molecular biomarkers for prostate cancer.Active surveillance for low-risk localized prostate cancer: what do men and their partners think?Patient acceptance of active surveillance as a treatment option for low-risk prostate cancer.Neutrophil and Lymphocyte Counts as Clinical Markers for Stratifying Low-Risk Prostate Cancer.Conditional probability of reclassification in an active surveillance program for prostate cancerNationwide, population-based study of prostate cancer stage migration between and within clinical risk categories."Choosing wisely" to reduce low-value care: a conceptual and ethical analysis.Preoperative predictors of pathologic stage T2a in low-risk prostate cancer: implications for focal therapy.Stage migration and grade inflation in prostate cancer: Will Rogers meets Garrison Keillor.
P2860
Q24289356-71DE561A-35C4-43AA-8E1B-7AC8506A085DQ29619860-2C856D7C-A1A6-43AC-8B66-3CAF7CFA2777Q33344237-A53388EE-77FB-4445-80EA-57D16F27E60DQ34028603-1697E1B5-0B64-4346-951D-B5F711D391D0Q34223622-C82A3EA0-D41C-4AA8-88B6-C19F4A4DE96BQ34419421-4FC141B8-1F58-41B6-A4B2-8016300E5671Q34602118-B7FA9446-CCBD-41CD-AB51-0B3205B72C19Q34679207-50C2E15C-A703-4E8A-8BEC-457898DE0246Q34733322-F751BBB4-88A6-458A-AEFC-93B2481CC33BQ34782101-FFE9F53E-0A5F-4BA7-BEE5-C103E802A110Q34817192-4B17CEF7-5AD6-4C4D-B917-68881C43040DQ35186071-1F9331AC-01D9-4DC4-BC1E-236A80B5F04DQ35700730-CF883E85-7135-4023-9C89-C26F04E3041AQ36336991-1403DEA0-6EB0-4608-A531-A967D693F221Q36450800-2C8CD262-20C1-43BB-8C96-DE29C0C95860Q36520543-BB762D6D-694D-483E-A651-EC23BCD6BC88Q36524465-8264F0A2-7C9B-410D-9AF6-D39B7DB3F295Q36757436-311027CD-2F66-4BA9-92E2-338D576A54DFQ36833353-A8327675-1872-41B0-B24A-65D44A5681ADQ36836075-EFBEC455-3227-4B9F-A509-75348282BB48Q37142197-5ED9BD44-77DF-47F7-9349-F914DACF1665Q37502285-C2BDE83E-2655-4B58-9B2B-B210B5889BC6Q37801615-5515150D-B7C7-4EF3-B8D6-2551CBDB425AQ37972703-9E9017CE-DCF4-4F1D-92E1-F6DE9FD01512Q39051878-08CE74B6-83D9-49DD-8298-A657F9CF095DQ39758890-A191ED51-E1F5-40D5-AA0A-CC0285DD6B24Q40572565-2CE4724B-CE64-4C48-8129-05B79700338CQ41495208-E8FBC05F-9747-4512-AB10-BFECCCCAC080Q45742174-689717FC-A74D-4C50-9C90-15D4F18CD538Q46729606-ABDB4D57-3FFA-4F0F-B7DA-02D411E69AD8Q46958510-B75296B4-E4AA-41E5-9856-CED9AB9BEAE3Q52991877-3D203B9F-F085-41F4-911B-9BBB249FDA2F
P2860
Time trends and characteristics of men choosing watchful waiting for initial treatment of localized prostate cancer: results from CaPSURE.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Time trends and characteristic ...... cancer: results from CaPSURE.
@en
Time trends and characteristic ...... cancer: results from CaPSURE.
@nl
type
label
Time trends and characteristic ...... cancer: results from CaPSURE.
@en
Time trends and characteristic ...... cancer: results from CaPSURE.
@nl
prefLabel
Time trends and characteristic ...... cancer: results from CaPSURE.
@en
Time trends and characteristic ...... cancer: results from CaPSURE.
@nl
P2093
P1476
Time trends and characteristic ...... cancer: results from CaPSURE.
@en
P2093
Deborah P Lubeck
Eric P Elkin
Maxwell V Meng
Peter R Carroll
Shilpa S Mehta
Susan R Harlan
P304
P356
10.1097/01.JU.0000091641.34674.11
P407
P577
2003-11-01T00:00:00Z